3Hutchens T W, Yip T T. New desorption strategies for the mass spectrometric analysis of macromolecules [J], Rapid Commun Mass Spectrom, 1993, 7:576-580.
4Issaq H J, Veenstra T D, Conrads T P, et al. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification[J]. Biochem Biophys Res Commun, 2002, 292(3):587-592.
5Issaq H J, Conrads T P, Prieto D A, et al. SELDI-TOF MS for diagnostic proteomics[J]. Anal Chem, 2003, 75(7):148A-155A.
6Zhu H, Snyder M. Protein Chip technology[J]. Curt Opin Chem Bio,2003, 7(1):55-63.
7Kas K. On the technicalities of discovering and applying protein biomarkers for-cancer prevention[J]. Eur J Cancer Prevention, 2004,13(5): 437-446.
8Banez L L, Prasanna P, Sun L, et al. Diagnostic potential of serum proteomic patterns in prostate cancer[J]. J Urol, 2003, 170(2Pt1):442-446.
9Ornstein D K, Ravford W, Fusaro V A, et al. Serum proteomic prostate specific antigen levels between 2.5 and 15.0 ng/ml[J]. J Urol,2004, 172(4Pt1): 1302-1305.
10Liu A Y, Zhang H, Sorensen C M, et al. Analysis of prostate cancer by proteomics using tissue specimens[J]. J Urol, 2005, 173(1):73-78.
4Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus [ J ]. Arthritis Rheum, 1997,40 ( 9 ) : 1725.
